In the U.S., 5,483 patients/year develop acute GvHD following an allogeneic HCT.
Study evaluating the safety, signs of efficacy, pharmacokinetics, receptor occupancy and pharmacodynamics biomarkers of Neihulizumab in patients with steroid-refractory acute GvHD
Ann Arbor, MIUniversity of Michigan
Ann Arbor, Michigan, United States, 48109
Minneapolis, MNUniversity of Minnesota
Minneapolis, Minnesota, United States, 55455
Nashville, TNVanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Seattle, WAFred Hutchinson
Seattle, Washington, United States, 98109
Milwaukee, WIMedical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Duarte, CACity of Hope
Duarte, California, United States, 91010
Roxanne Garcia/Golnaz Namdar
Atlanta, GAEmory University
Atlanta, Georgia, United States, 30322
Chicago, ILUniversity of Chicago
Chicago, Illinois, United States, 60637
Graft-versus-host disease (GvHD) is a multisystem disorder that occurs after an allogeneic hematopoietic cell transplant (HCT) when immune cells (T cells) from the donor (the graft) recognize the transplant recipient (the host) as foreign, initiating an immune reaction that causes disease in the transplant recipient.
Allogeneic hematopoietic cell transplantation is a common treatment for many different cancers, particularly relapse of hematological malignancies (such as leukemia or lymphoma), as well as some other (non-cancer) conditions that affect the blood or immune system. In addition to HCT procedures, GvHD can also occur after transplantation of solid organs that may contain immune cells such as T cells.
GvHD is a significant cause of medical problems and death following an allogeneic HCT. Somewhere between 30 and 70 percent of transplant recipients develop acute GvHD, depending on donor type, transplant technique and other factors.
GvHD primarily affects the skin, the liver and the gastrointestinal tract. Some people have a very mild form, which doesn’t last long. For others, GvHD can be severe, and in some cases, may even be life threatening. Some people may have GvHD over many years, or even a lifetime.